Enzyme inhibition and induction in liver disease

Current Clinical Pharmacology

Volumn 3, Issue 1, 2008, Pages 56-69

  Palatini, Pietro ^a   De Martin, Sara ^a   Pegoraro, Paola ^a   Orlando, Rocco ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Cytochrome P450; Drug metabolizing enzymes; Enzyme induction; Enzyme inhibition; Liver disease

Indexed keywords

3 METHYLXANTHINE; 7 ETHOXYCOUMARIN; ALCOHOL; AMINOPHENAZONE; ANDROSTANE DERIVATIVE; CYTOCHROME P450 1A1; CYTOCHROME P450 2C; CYTOCHROME P450 2E1; DIAZEPAM; DRUG METABOLIZING ENZYME; ERYTHROMYCIN; FLUVOXAMINE; GLUTETHIMIDE; HEXOBARBITAL; HYPOXIA INDUCIBLE FACTOR 1BETA; LIDOCAINE; OMEPRAZOLE; PARACETAMOL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PHENAZONE; PHENOBARBITAL; PHENYLBUTAZONE; PHENYTOIN; PLACEBO; PREGNANE X RECEPTOR; PROPRANOLOL; RIFAMPICIN; THEOPHYLLINE; TOLBUTAMIDE; UNINDEXED DRUG;

BIOTRANSFORMATION; DRUG ANTAGONISM; DRUG CLEARANCE; DRUG DISPOSITION; DRUG HALF LIFE; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME INDUCTION; ENZYME INHIBITION; GENETIC POLYMORPHISM; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIVER CIRRHOSIS; LIVER DISEASE; LIVER DYSFUNCTION; LIVER FUNCTION; LIVER FUNCTION TEST; LIVER SINUSOID; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW;

ANIMALS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; ENZYME INDUCTION; ENZYME INHIBITORS; FLUVOXAMINE; HUMANS; LIDOCAINE; LIVER; LIVER DISEASES; THEOPHYLLINE;

EID: 38949102772     PISSN: 15748847     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488408783329896     Document Type: Review

References (73)

1. Tucker GT, Huston B, Huang SW. Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential - toward a consensus. Clin Pharmcol Ther 2001; 70: 103-14.
2. Roden DM. In: Harrison's Principles of Internal Medicine. New York, McGraw - Hill 2005; 13-25.
3. Lin JH, Lu AYH. Inhibition and induction of cytochrome P450 and the clinical implications. Clin Pharmacokinet 1998; 35: 361-90.
4. Bachmann KA, Lewis JD. Predicting inhibitory drug-drug interactions and evaluating drug interaction reports using inhibition constants. Ann Pharmacother 2005; 39: 1064-72.
5. Park BK, Kitteringham NR, Pirmohamed M, Tucker GT. Relevance of induction of human drug-metabolizing enzymes: pharmacological and toxicological implications. Br J Clin Pharmacol 1996; 41: 447-91.
6. Fuhr U. Induction of drug metabolizing enzymes. Pharmacokinetic and toxicological consequences in humans. Clin Pharmacokinet 2000; 38: 493-504.
7. Strand LM, Morley PC, Cipolle RJ, Ramsey R, Lamsam GD. Drug-related problems: their structure and function. DICP 1990; 24: 1093-7.
8. Obach RS, Walsky RL, Venkatakrishnan K, Hustion BJ, Tremaine LM. In vivo cytochrome P450 inhibition data and the prediction of drug-drug interactions: qualitative relationships, quantitative predictions, and the rank-order approach. Clin Pharmacol Ther 2005; 78: 582-92.
9. Cheng PY, Morgan ET. Hepatic cytochrome P450 regulation in disease states. Curr Drug Metab 2001; 2: 165-183.
10. Lee LS, Nafziger AN, Bertino JS. Evaluation of inhibitory drug interactions during drug development: genetic polymorphism must be considered. Clin Pharmacol Ther 2005; 78: 1-6.
11. Ma Q, Lu AHY. Origins of individual variability in P4501A induction. Chem Res Toxicol 2003; 16: 249-60.
12. Tang C, Lin JH, Lu AYH. Metabolism-based drug-drug interactions: what determines individual variability in cytochrome P450 induction? Drug Metab Dispos 2005; 33: 603-13.
13. Huet PM, Villeneuve JP, Fenyves D. Drug elimination in chronic liver disease. J Hepatol 1997; 26: 63-72.
14. Conn HO. A peek at the Child - Turcotte classification. Hepatology 1981; 6: 673-76.
15. Pugh RNH, Murray-Lion IM, Dawson JL, Pietroni MC, Williams R. Transection of the aesophagus for bleeding oesophageal varices. Br J Surg 1973; 60: 646-49.
16. Ohnishi K. Pharmacokinetics of famotidine after intravenous administration in liver disease. Am J Gastroenterol 1991; 86: 41-5.
17. Morgan DJ, McLean AJ. Clinical pharmacokinetic and pharmacodynamic considerations in patients with liver disease. An update. Clin Pharmacokinet 1995; 29: 370-91.
18. Hasler JA, Estabrook R, Murray M, et al. Human cytochromes P450. Mol Aspects Med 1999; 20: 1-137.
19. Elbekai RH, Korashy HM, El-Kadi OS. The effect of liver cirrhosis on the regulation and expression of drug metabolizing enzymes. Curr Drug Metab 2004; 5: 157-67.
20. Howden CW, Birnie GC, Brodie MJ. Drug metabolism in liver disease. Pharm Ther 1989; 40: 439-74.
21. Orlando R, Piccoli P, De Martin S, Padrini R, Floreani M, Palatini P. Cytochrome P450 1A2 is a major determinant of lidocaine metabolism in vitro: effects of liver function. Clin Pharmacol Ther 2004; 75: 80-8.
22. Orlando R, Padrini R, Perazzi M, De Martin S, Piccoli P, Palatini P. Liver dysftmction markedly decreases the inhibition of cytochrome P450 1A2-mediated theophylline metabolism by fluvoxamine. Clin Pharmacol Ther 2006; 79: 489-99.
23. Kawasaki S, Imamura H, Bandai Y, Sanjo K, Idezuki Y. Direct evidence for the intact hepatocyte theory in patients with liver cirrhosis. Gastroenterology 1992; 102: 1351-5.
24. Taylor A, Granger DN. In: Handbook of Physiology, Bethesda, American Physiological Society 1984; 467-520.
25. Wisse E, De Zanger RB, Charels K, Van Der Smissen P, McCuskey RS. The liver sieve: considerations concerning the structure and function of endothelial fenestrae, the sinusoidal wall and the space of Disse. Hepatology 1985; 5: 683-92.
26. Fenyves D, Gariépy L, Villeneuve JP. Clearance by the liver in cirrhosis. I. Relationship between propranolol metabolism in vitro and its extraction by the perfused liver in the rat Hepatology 1993; 17: 301-6.
27. Gariépy L, Fenyves D, Kassissia I, Villeneuve JP. Clearance by the liver in cirrhosis. II. Characterization of propranolol uptake with the multiple indicator dilution technique. Hepatology 1993; 18: 823-31.
28. Hung DY, Chang P, Cheung K, et al. Cationic drug pharmacokinetics in diseased livers determined by fibrosis index, hepatic protein content, microsomal activity, and nature of drug. J Pharmacol Exp Ther 2002; 301: 1079-87.
29. McLean AJ, Morgan DJ. Clinical pharmacokinetics in patients with liver disease. Clin Pharmacokinet 1991; 21: 42-69.
30. Le Couteur DG, Fraser R, Hilmer S, Rivory LP, McLean AJ. The hepatic sinusoid in aging and cirrhosis. Effects on hepatic substrate disposition and drug clearance. Clin Pharmacokinet 2005; 44: 187-200.
31. Hickey PL, Angus PW, McLean AJ, Morgan DJ. Oxygen supplementation restores theophylline clearance to normal in cirrhotic rats. Gastroenterology 1995; 108: 1504-9.
32. Froomes PRA, Morgan DJ, Smallwood RA, Angus PW. Comparative effects of oxygen supplementation on theophylline and acetaminophen clearance in human cirrhosis. Gastroenterology 1999; 116: 915-20.
33. Murray M. Mechanisms and significance of inhibitory drug interactions involving cytochrome P450 enzymes (Review). Int J Mol Med 1999; 3: 227-38.
34. Parkinson A, Mudra DR, Johnson C, Dwyer A, Carroll KM. The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes. Toxicol Appl Pharmacol 2004; 199: 193-209.
35. Zhou S, Clan SY, Gob BC, et al. Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin Pharmacokinet 2005; 44: 279-304.
36. De Martin S, Orlando R, Bertoli M, Pegoraro P, Palatini P. Differential effect of chronic renal failure on the pharmacokineties of lidocaine in patients receiving and not receiving hemodialysis. Clin Pharmacol Ther 2006; 80: 597-606.
37. Bargetzi MJ, Aoyama T, Gonzales FJ, Meyer UA. Lidocaine metabolism in human liver microsomes by cytochrome P450 IIIA4. Clin Pharmacol Ther 1989; 46: 521-7.
38. Orlando R, Piccoli P, De Martin S, Padrini R, Palatini P. Effect of the CYP3A4 inhibitor erythromycin on the pharmacokinetics of lignocaine and its pharmacologically active metabolites in subjects with normal and impaired liver function. Br J Clin Pharmacol 2003; 55: 86-93.
39. Huet PM, Villeneuve JP. Determinants of drug disposition in patients with cirrhosis. Hepatology 1983; 3: 913-8.
40. Wang JS, Backman JT, Taavitsainen P, Neuvonen P, Kivistö KT. Involvement of CYP1A2 and CYP3A4 in lidocaine N-deethylation and 3-hydroxylation in humans. Drug Metab Dispos 2000; 28: 959-65.
41. Piafsky KM, Sitar DS, Rangno RE, Ogilvie RI. Theophylline disposition in patients with hepatic cirrhosis. N Engl J Med 1977; 296: 1495-7.
42. Pieper JA, Lima H. In: Applied Pharmacokinetics. Principles of Therapeutic Drug Monitoring. (Evans WE, Schentag JJ, Jusko WJ, eds.). Vancouver (WA), Applied Therapeutics 1992; chap. 21, p. 6-9.
43. Mankowski DC, Ekins S. Prediction of human drug metabolizing enzyme induction. Curr Drug Metab 2003; 4: 381-91.
44. Tirona RG, Kim RB. Nuclear receptors and drug disposition gene regulation. J Pharm Sci 2005; 94: 1169-86.
45. Lonard DK O'Malley BW. The expanding cosmos of nuclear receptor coactivators. Cell 2006; 125: 411-4.
46. Schuetz EG. Induction of cytochromes P450. Curr Drug Metab 2001; 2: 139-47.
47. Tirona RG, Leake BF, Wolkoff AW, Kim RB. Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation. J Pharmacol Exp Ther 2003; 304: 223-28.
48. Schuetz EG, Schinkel AH, Relling MV, Schueti. JD. P-glycoprotein: a major determinant of rifampicin-inducible expression of cytochrome P4503A in mice and humans. Proc Natl Acad Sci USA 1996; 93: 4001-5.
49. de Morais SM, Goldstein JA, Xie HG, et al. Genetic analysis of the S-mephenytoin polymorphism in a Chinese population. Clin Pharmacol Ther 1995; 58: 405-11.
50. Lin P, Hu SW, Chang TH. Correlation between gene expression of aryl hydrocarbon receptor (AhR), hydrocarbon receptor nuclear translocator (Arnt), cytochromes P4501A1 (CYP1A1) and 1B1 (CYP1B1), and inducibility of CYP1A1 and CYP1B1 in human lymphocytes. Toxicol Sci 2003; 71: 20-6.
51. Okey AB, Manchester DK, Feeley MM, Grant DL, Gilman A. Ah receptor charactetization in human placenta samples. Organohalogen Compd 1995; 177-84.
52. Salem SA, Rajjayabun P, Shepherd AM, Stevenson IH. Reduced induction of drug metabolism in the elderly. Age Ageing 1978; 7: 68-73.
53. Dilger K, Hofmann U, Klotz U. Enzyme induction in the elderly: effect of rifampin on the pharmacokinetics and pharmacodynamics of propafenone. Clin Pharmacol Ther 2000; 67: 512-20.
54. Fromm MF, Dilger K, Busse D, Kroemer HK, Eichelbaum M, Klotz U. Gut wall metabolism of verapamil in older people: effects of rifampicin-mediated enzyme induction. Br J Clin Pharmacol 1998; 45: 247-55.
55. Pascussi JM, Gerbal-Chaloin S, Pichard-Garcia L, et al. Interleukin-6 negatively regulates the expression of pregnane X receptor and constitutively activated receptor in primary human hepatocytes. Biochem Biophys Res Commun 2000; 274: 707-13.
56. Hoyumpa AM, Shenker S. Major drug interactions: effect of liver disease, alcohol, and malnutrition. Ann Rev Med 1982; 33: 113-49.
57. Marshall WJ, McLean AEM. The effect of cirrhosis of the liver on microsomal detoxications and cytochrome P-450. Br J Exp Path 1969; 50: 578-83.
58. Farrell GC, Zaluzny L. Microsomal protein synthesis and induction of cytochrome P-450 in cirrhotic rat liver. Aust J Exp Piol Med Sci 1984; 62: 291-301.
59. Wu Z, Piché D., Vallières S, Huet PM, Gascon-Barré M. Unimpaired induction of drug-metabolizing enzymes in hepatocytes isolated from rats with micronodular cirrhosis. Can J Physiol Pharmacol 1991; 69: 426-36.
60. Levi AJ, Sherlock S, Walker D. Phenylbutazone and isoniazid metabolism in patients with liver disease in relation to previous drug therapy. Lancet 1968; 1: 1275-9.
61. Zilly W, Breimer DD, Richter E. Stimulation of drug metabolism by rifampicin in patients with cirrhosis or cholestasis measured by increased hexobarbital and tolbutamide clearance. Eur J Clin Pharmacol 1977; 11: 287-93.
62. Piken E, Hepner GW. Decreased hepatic microsomal riserve in patients with cirrhosis. Studies using aminopyrine as model drug. J Lab Clin Med 1979; 94: 947-54.
63. Thaler MM, Dallman PR. Phenobarbital-induced changes in NADPH-cytochrome c reductase and smooth endoplasmic reticulum in human liver. J Pediatr 1972; 80: 302-10.
64. Capelle P, Dhumeaux D, Mora M, Feldmann G, Berthelot P. Effect of rifampicin on liver function in man. Gut 1972; 13: 366-71.
65. Branch RA, Herbert CM, Read AE. Determinants of serum antipyrine half-lives in patients with liver disease. Gut 1973; 14: 569-73.
66. Lewis KO, Nicholson G, Lance P, Paton A. Aminopyrine breath test in alcoholic liver disease and in patients on enzyme-inducing drugs. J Clin Pathol 1977; 30: 1040-3.
67. Farrell GC, Cooksley WGE, Powell LW. Drug metabolism in liver disease: activity of hepatic microsomal metabolizing enzymes. Clin Pharmacol Ther 1979; 26: 483-92.
68. Farrell GC, Cooksley WGE, Powell LW. Enhancement of hepatic drug metabolism by glutethimide in patients with liver disease. Eur J Clin Pharmacol 1979; 16: 113-17.
69. Miguet JP, Vuitton D, Thebault-Lucas A, Joanne C, Dhumeaux D. Spironolactone and enzyme induction in patients with alcoholic cirrhosis. Gastroenterology 1980; 78: 996-1000.
70. Herold C, Ganslmayer M, Ocker M, et al. Inducibility of microsomal liver function may differentiate cirrhotic patients with maintained compared with severely compromised liver reserve. J Gastroenterol Hepatol 2003; 18: 445-9.
71. Joeres R, Klinker H, Heusler H, Epping J, Zilly W, Richter E. Influence of smoking on caffeine elimination in healthy volunteers and in patients with alcoholic liver cirrhosis. Hepatology 1988; 8: 575-9.
72. Coverdale S, Byth K, Field J, Liddle C, Lin R, Farrell GC. Antipyrine clearance and response to interferon treatment in patients with chronic active hepatitis C. Hepatology 1995; 22: 1065-71.
73. FDA guidance for industry. Pharmacokinetics in patients with impaired hepatic function - study design, data analysis, and impact on dosing and labeling. Rockville (MD): Food and Drug Administration; 1999.